A Study of GSK573719 in Healthy Japanese Male Subjects

Phase 1

Completed

• Conditions: Pulmonary Disease, Chronic Obstructive
• Interventions: Drug: GSK573719 matching Placebo; Drug: GSK573719 250 μg; Drug: GSK573719 500 μg; Drug: GSK573719 1000 μg

• Registration Number: NCT01013974
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This is a single centre, randomized, double blind, placebo controlled, single and repeat dose study to investigate the safety, tolerability, and pharmacokinetics of inhaled dose of GSK573719 with lactose and containing magnesium stearate by a novel dry powder device in healthy Japanese male subjects.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-10-05
• Study First Submitted: 2009-11-12
• Study First Submitted QC: 2009-11-12
• Study First Posted: 2009-11-16
• Primary Completion: 2009-12-18
• Study Completion: 2009-12-18
• Status Verified: 2017-08
• Last Update Submitted: 2017-08-01
• Last Update Posted: 2017-08-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 48

Inclusion Criteria

1. Japanese healthy male subjects aged between 20 and 64 years of age inclusive. Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination, laboratory studies, and other tests.

2. Body weight ≥ 50kg and BMI within the range 18.5-25.0kg/m2 inclusive.

3. Non-smokers (never smoked or not smoking for >6 months with <10 pack years history (Pack years = (cigarettes per day smoked/20) x number of years smoked))

4. Normal spirometry (FEV1 ≥ 80% of predicted, FEV1/FVC ≥ 70%).

5. Clinical laboratory tests data obtained at screening meet the following:

   AST(GOT), ALT(GPT), total-bilirubin: below the upper limit of the normal ranges

6. Normal 12-lead EGC finding at screening; QTc(B) interval <450msec

7. A mean blood pressure lower than 140/90mmHg at screening.

8. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

9. Capable of using the novel dry powder inhaler.

Exclusion Criteria

1. The subject has any clinically relevant abnormality on medical examination, vital sign, clinical laboratory test or medical history at screening in the medical opinion of the investigator or the subject has a medical history that is not considered as eligible for inclusion in this study by the investigator.
2. The subject is positive for syphilis, HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody.
3. The subject is positive for urine drug screening.
4. The subject has an allergy for any drug or idiosyncrasy
5. The subject has a history of breathing problems (i.e. history of asthmatic symptomatology).
6. The subject has a history of cardiovascular disease.
7. The subject has a significant clinical history or current conditions of glaucoma.
8. The subject has a significant clinical history or current conditions of prostatic hypertrophy.
9. The subject has a history of drug abuse or alcoholism.
10. The subject has a history of cholecystectomy or biliary tract disease.
11. History of regular alcohol consumption exceeding on average, 14 drinks/week (1 drink = 5 ounces (150 mL) of wine or 350 mL of beer or 1.5 ounces (45 mL) of 80 proof distilled spirits) within 6 month of screening.
12. Use of prescription or non-prescription drugs, including CYP3A/PGP inhibitor, vitamins, herbal and dietary supplements (including St John'sWort) within 14 days prior to the first dose of study medication.
13. The subject is currently participating in another clinical study or post-marketing study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.
14. The subject has participated in a clinical study with an investigational or a non-investigational drug or device during the previous 4 months.
15. The subject has an allergy for any drug hypersensitivity to milk protein or the excipients lactose monohydrate and magnesium stearate.
16. The subject has donated a unit of blood ">400 mL" within the previous 4 months or ">200 mL" within the previous 1 month.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	GSK573719 matching Placebo	Each subject will receive GSK573719 matching placebo on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
GSK573719 250 microgram (μg) arm	GSK573719 250 μg	Each subject will receive the first dose of GSK573719 250 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
GSK573719 500 μg arm	GSK573719 500 μg	Each subject will receive the first dose of GSK573719 500 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
GSK573719 1000 μg arm	GSK573719 1000 μg	Each subject will receive the first dose of GSK573719 1000 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.

Primary Outcome Measures

Name	Time	Method
PK: Cmax, tmax and AUC(0-t)

Trial Locations

Locations (1)

GSK Investigational Site; 🇯🇵 Kagoshima, Japan